常规的临床实践:慢性乙型肝炎NUC初治患者恩替卡韦的有效性

StephenW

<http://www.mdlinx.com/infectious-disease/newsl-article.cfm/3685834/ZZ680655367925639220014/?news_id=497&newsdt=072011&subspec_id=130>
常规的临床实践:
慢性乙型肝炎NUC初治患者恩替卡韦的有效性


Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in
routine clinical practice

International Journal of Clinical Practice, 07/20/2011  Clinical Article

Ridruejo E et al. - The entecavir (ETV) monotherapy showed high virological
response rates, a favourable safety profile for NUC-naive HBeAg-positive
and negative patients treated in routine clinical practice.

Methods

• Sixty-nine HBeAg positive and negative NUC naïve chronic HBV patients
were treated with ETV for 110 weeks.

• 63% were HBeAg positive, 16% were cirrhotics, mean HBV-DNA was 7.09 log
IU/ml and mean ALT was 157 IU/ml.

Results

• Sixty-one (88%) patients achieved undetectable DNA, with 46%, 77% and
100% virological response rates at week 24, 48 and 96 of treatment,
respectively.

• Thirty-seven (84%) patients in the HBeAg-positive population achieved
undetectable DNA, with 67% and 100% virological response rates at week 48
and 96 of treatment, respectively.

• Twenty-four (96%) patients in the HBeAg-negative population achieved
undetectable DNA, with 91% and 100% virological response rates at week 48
and 96 of treatment, respectively.

• Twenty-three (53%) patients cleared HBeAg and 19 (44%) patients
seroconverted to antiHBe positive status; seven (10%) patients cleared
hepatitis B surface antigen and five (7%) patients developed antiHBs.

• At the end of the study, 10 patients successfully stopped therapy: nine
HBeAg positive (four developed antiHBs positive) and one HBeAg negative.

• None of the patients had primary non-response.

• ETV resistance was not tested.

• None of the patients developed hepatocellular carcinoma, underwent
liver transplantation or died because of liver-related events.

• No serious adverse events were reported.

Read this article in International Journal of Clinical Practice

<http://www.ingentaconnect.com/content/bsc/ijcp/2011/00000065/00000008/art00008>

kennyu

StephenW 发表于 2011-7-26 12:56
常规的临床实践:
慢性乙型肝炎NUC初治患者恩替卡韦的有效性

这个结果很不寻常啊，以往接触的NT的临床数据，极少情况下，
会出现HBsAg的转换。这个结果竟然能有这么高的转化率。
有些怀疑。

StephenW

谷歌翻译不是100％准确，仅供参考使用。

方法

•六十九个HBeAg的正面和负面的NUC初治的慢性乙肝患者
ETV治疗为110周。

•63％，HBeAg阳性，16％的肝硬化患者，平均HBV - DNA为7.09log IU / ml和平均ALT 157 IU / ml的。

结果

•60（88％）的患者达到46％检测不到DNA，77％和100％，分别在治疗24周，48周和96周的病毒学应答率。

•37（84％）患者在HBeAg阳性组检测不到DNA，67％和100％，分别48周时和96周的病毒学应答率。

•二十四（96％）患者在HBeAg阴性组实现检测不到DNA，91％和100％，分别48周时和96周的病毒学应答率。

•二十三（53％）患者清除HBeAg和19例（44％）血清阳转，以antiHBe积极的状态，7例（10％）患者清除乙肝表面抗原和5例（7％）获得antiHBs。

•在研究结束时，10名患者成功地停止治疗：九HBeAg阳性（4获得antiHBs阳性）和HBeAg阴性。

•没有病人有原发性非响应。

•ETV耐药没有测试。

•病人无肝癌，经历肝移植或死亡的，因为肝相关的事件。

•无严重不良事件的报告。

阅读这篇文章在国际期刊临床实践

<http://www.ingentaconnect.com/co ... 0000008/art00008>;
b葡萄牙学会Sangue，葡萄牙波尔图

StephenW

kennyu 发表于 2011-7-26 13:05
这个结果很不寻常啊，以往接触的NT的临床数据，极少情况下，
会出现HBsAg的转换。这个结果竟然能有这么高 ...

This is a very small sample from Portugal (I think), Genotype unknown, years of infection unknown.